CDK2 and hepatocellular carcinoma: The antiproliferative effects of withaferin A in human hepatocellular carcinoma (HCC) cells caused G1-phase cell cycle arrest with upregulation of p53, p21, as well as Bax, and downregulated the activation of Bcl-2, CDK2, and cyclin D1 [128].